The authors assessed the patient characteristics associated with RSV vaccination among older adults hospitalized during the ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

Contracting a non-COVID lower respiratory tract infection raises the risk of death 2 to 7 times over the next month to a year ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

The following is a summary of “Clinical diagnostic value of throat swabs in pediatric acute lower respiratory tract ...

Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...